Patent 11123331

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

Active provider: Google · gemini-2.5-flash

No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.

Cases on file (4)

Group view →

Specific litigation cases in our database that name US patent 11123331. The free-form analysis below may also discuss cases beyond this list.

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

✓ Generated

The previous analysis stated that a search of CAFC dockets for 2026 did not reveal any litigation involving US Patent 11,123,331. However, the search results indicate active litigation. The Google Patents link for US11123331B2 itself lists several litigation cases in the Delaware District Court. Furthermore, a Law Street Media article from July 8, 2022, and a JD Supra article from November 20, 2024, explicitly mention litigation involving this patent.

Here's a list of known litigation involving US Patent 11,123,331:

  • Case 1:

    • Plaintiff(s): Veloxis Pharmaceuticals, Inc.
    • Defendant(s): Accord Healthcare, Inc. and Intas Pharmaceuticals LTD
    • Jurisdiction: District of Delaware
    • Case Number: 1:22-cv-00909
    • Filing Date: July 7, 2022 (based on "filed suit on Thursday" on July 8, 2022)
    • Outcome/Current Status: The complaint alleges patent infringement due to the defendants' submission of Abbreviated New Drug Applications (ANDA) for generic tacrolimus extended-release tablets. Veloxis is seeking favorable judgment, an order preventing manufacturing, and damages. This case is active.

  • Case 2:

    • Plaintiff(s): Veloxis Pharmaceuticals, Inc.
    • Defendant(s): Alkem Labs. Ltd.
    • Jurisdiction: District of Delaware
    • Case Number: 24-0784 (D. Del.)
    • Filing Date: July 3, 2024
    • Outcome/Current Status: This appears to be an ANDA case concerning Envarsus XR® (tacrolimus extended-release tablets). This case is active.

  • Case 3:

    • Jurisdiction: Delaware District Court
    • Case Number: 1:24-cv-00726
    • Filing Date: Not explicitly stated, but within 2024 based on case number.
    • Plaintiff(s): Not explicitly stated in the provided snippet, but likely Veloxis Pharmaceuticals Inc. given the patent ownership.
    • Defendant(s): Not explicitly stated in the provided snippet.
    • Outcome/Current Status: Listed as active litigation.

  • Case 4:

    • Jurisdiction: Delaware District Court
    • Case Number: 1:24-cv-00784
    • Filing Date: Not explicitly stated, but within 2024 based on case number.
    • Plaintiff(s): Not explicitly stated in the provided snippet, but likely Veloxis Pharmaceuticals Inc. given the patent ownership.
    • Defendant(s): Not explicitly stated in the provided snippet.
    • Outcome/Current Status: Listed as active litigation.

  • Case 5:

    • Jurisdiction: Delaware District Court
    • Case Number: 1:25-cv-00458
    • Filing Date: Not explicitly stated, but within 2025 based on case number.
    • Plaintiff(s): Not explicitly stated in the provided snippet, but likely Veloxis Pharmaceuticals Inc. given the patent ownership.
    • Defendant(s): Not explicitly stated in the provided snippet.
    • Outcome/Current Status: Listed as active litigation.

Generated 5/30/2026, 12:45:46 PM